Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2025
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocksCombined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).
Bsteh D, Buckley J, Mitchell S, Ostrow D, Parmentier J, Jahan S, Sadis S, Smith J, NI J, Peng X, McConkey D, Dorff T, Lerner S, Aparicio A, Chapin B, Duddalwar V, Triche T, Goldkorn A. Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17111.Peer-Reviewed Original ResearchProspective phase 3 trialsSingle nucleotide variantsCopy number variantsPhase 3 trialProstate cancerTime pointsProstate cancer-relevant genesCirculating tumor cell DNALiquid biopsy componentsMetastatic prostate cancerMultiple time pointsIon Reporter softwareRecurrent copy number variantsTumor cell DNACell-free DNASingle tube of bloodCancer-relevant genesThermo FisherTubes of bloodPrimary tumorSystemic therapyDefinitive treatmentCtcDNAIndeterminate significancePreservation tubesTRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, Chi K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps5129.Peer-Reviewed Original ResearchMetastatic castration sensitive prostate cancerAndrogen receptor pathway inhibitorsAndrogen deprivation therapyPSA responseOverall survivalDisease volumePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyReceipt of androgen deprivation therapyResponse to androgen deprivation therapyMonths of androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalMonths median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPrimary prostate cancer tissuesNational Clinical Trials NetworkPhase III clinical trialsUrine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
St-Laurent M, Singh P, McConkey D, Lucia M, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzarella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology 2025 PMID: 40404526, DOI: 10.1016/j.eururo.2025.03.023.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerUrine tumor DNAEvent-free survivalTumor DNABladder cancerBCG-unresponsive NMIBCPatients treated with atezolizumabRisk of treatment failureClinical evidence of diseaseRisk of recurrenceEvidence of diseaseSystemic immunotherapyTreatment failureTherapeutic decisionsClinical evidencePatientsUrine samplesAtezolizumabBaselineCancerUrineTreatmentRiskImmunotherapySWOGA festschrift in honor of Ian M. Thompson Jr., MD
Svatek R, Ankerst D, D' Amico A, Flaig T, Ford L, Goldkorn A, Hernandez J, Kumar A, Leach R, Lerner S, Liss M, McConkey D, Minasian L, Morilak D, Mueller E, Parekh D, Platz E, Sudarshan S, Unger J. A festschrift in honor of Ian M. Thompson Jr., MD. Urologic Oncology Seminars And Original Investigations 2025, 43: 423-435. PMID: 40447392, DOI: 10.1016/j.urolonc.2024.10.030.Peer-Reviewed Original ResearchPredicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsIMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-Cause MortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodIMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerBladder sparing therapyAll-Cause MortalityOncological outcomesRadical cystectomyCancer-specific mortalityNon-invasive diseaseBCG-unresponsiveBladder cancerPathological outcomesT1 diseaseT1 patientsCIS patientsMedian timeProgression to muscle-invasive bladder cancerBCG-unresponsive NMIBC patientsImpact of pathological stageImpact of tumor stageInternational cohortMuscle-invasive bladder cancerAssociated with significant morbiditySingle-institution seriesHeterogeneous group of patientsCompare oncologic outcomesINCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG
Narayan V, Boorjian S, Crispen P, Kamat A, Gomella L, Kates M, Karsh L, Master V, Richards K, Lerner S, Kim E, Inman B, Lane B, Schuckman A, Krupski T, Bardot S, Montgomery J, Busby J, Luchey A, Williams M, Agarwal P, Rehm D, Jakobsen J, Juul K, Dinney C. INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG. Urologic Oncology Seminars And Original Investigations 2025, 43: 86. DOI: 10.1016/j.urolonc.2024.12.217.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle-invasive bladder cancerCystectomy-free survivalCarcinoma in situNadofaragene firadenovecPhase 3 studyCR statusBladder cancerKaplan-MeierPathological outcomesVector-based gene therapyMedian follow-up timeBladder-sparing optionsHigh-grade recurrenceYears of follow-upRate of upstagingKaplan-Meier (KMAssociated with morbidityData cutoffImmediate cystectomyTransurethral resectionPapillary tumorsOpen-labelDefinitive treatmentEfficacy analysisB2B: Bladder Cancer Summary
Black P, Lerner S, Desai M, Konety B, Gupta S, Joshi A, Oualla K, Rajappa S, Talwar V, Prakash G, Tanguay S. B2B: Bladder Cancer Summary. Société Internationale D’Urologie Journal 2025, 6: 18. DOI: 10.3390/siuj6010018.Peer-Reviewed Original Research